<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="1" ids="16347,3424">Carnitine</z:chebi> plays a key role in energy production in the myocardium </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="1" ids="16347,3424">Carnitine</z:chebi> deficiency commonly occurs in patients on <z:hpo ids='HP_0011010'>chronic</z:hpo> hemodialysis (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) and may contribute to <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: <z:chebi fb="1" ids="16347,3424">Carnitine</z:chebi> levels and cardiac function of nine children on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> were assessed before and after 6 months of intravenous <z:chebi fb="0" ids="16347">levocarnitine</z:chebi> supplementation </plain></SENT>
<SENT sid="3" pm="."><plain>Standard echocardiographic (ECHO) measures of left ventricular (LV) function as well as strain and strain rate analysis using novel speckle-tracking echocardiography were performed and the results compared to those of a control group of children on <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Following <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> supplementation, total (49.0 ± 1.67 vs. 298.0 ± 31.8 μmol/L) and free <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> (29.0 ± 1.20 vs. 180.4 ± 19.2 μmol/L) increased (p &lt; 0.0001), and the acyl:free (A:F) <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> ratio improved (0.73 ± 0.04 vs. 0.65 ± 0.05; p = 0.02) </plain></SENT>
<SENT sid="5" pm="."><plain>There were no changes in standard ECHO measures of LV function, including end diastolic dimension, mass index, ejection fraction, and fractional shortening </plain></SENT>
<SENT sid="6" pm="."><plain>There was significant (p = 0.017) improvement in the longitudinal strain rate (-1.48 ± 0.11 vs -1.91 ± 0.12) after <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> supplementation in the study group </plain></SENT>
<SENT sid="7" pm="."><plain>No improvements in LV function, strain, or strain rate occurred in controls </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="16347">Levocarnitine</z:chebi> supplementation improved <z:chebi fb="1" ids="16347,3424">carnitine</z:chebi> levels, the A:F ratio, and longitudinal strain rate in children on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> </plain></SENT>
</text></document>